Hydroxyapatite coating does not improve uncemented stem survival after total hip arthroplasty!

Figures & data

Table 1. Procedures sorted according to stem brand in each country, after exclusion of stem brands used in less than 500 cases per country, and after exclusion of all diagnoses other than osteoarthritis or pediatric hip disease

	Denmark	Norway	Sweden	Finland	Total
Total	35,513	20,850	22,829	36,877	116,069
Bimetric	20,192	0	5,137	17,402	42,731
Corail	7,067	14,581	5,125	1,454	28,227
CLS	2,218	0	7,569	0	9,787
ABG	0	499	3,010	5,363	8,872
Synergy	714	0	0	2,564	3,278
Summit	0	0	0	3,166	3,166
Accolade	0	0	1,157	1,817	2,974
Filler	0	2,328	0	0	2,328
ML-Taper	0	0	0	2,214	2,214
Bicontact	1,580	0	0	0	1,580
Profemur	407	0	0	893	1,300
Anca-Fit	1,100	0	0	0	1,100
Omnifit	0	686	0	398	1,084
SCP	0	1,073	0	0	1,073
Hactiv	0	1,023	0	0	1,023
Symax	962	0	0	0	962
Anthology	0	0	0	898	898
Cone	0	0	831	0	831
Taperloc	0	0	0	708	708
Zweymuller	0	660	0	0	660
Versys	659	0	0	0	659
AML	614	0	0	0	614

Stem brands are ordered by total number in descending order.

Table 2. Presence or absence of HA coating on the 22 stem brands included

	no HA coating	HA coating	Total
Total	57,255	58,814	116,069
Bimetric	31,768	10,963	42,731
Corail	0	28,227	28,227
CLS	9,741	46	9,787
ABG	0	8,872	8,872
Synergy	3,278	0	3,278
Summit	3,166	0	3,166
Accolade	0	2,974	2,974
Filler	243	2,085	2,328
ML-Taper	2,214	0	2,214
Bicontact	1,580	0	1,580
Profemur	895	405	1,300
Anca-Fit	0	1,100	1,100
Omnifit	0	1,084	1,084
SCP	0	1,073	1,073
Hactiv	0	1,023	1,023
Symax	0	962	962
Anthology	898	0	898
Cone	831	0	831
Taperloc	708	0	708
Zweymuller	660	0	660
Versys	659	0	659
AML	614	0	614

Stems are ordered by total number in descending order. There were no missing data on HA coating.

Table 3. Sex-, diagnosis-, and age distribution according to whether or not the stem had HA coating

	No HA coating		HA coating
	n	%	n	%
Male	28,277	49	25,928	44
Female	28,978	51	32,886	56
Sum	57,255	100	58,814	100
OA	54,520	95	52,965	90
Pediatric	2,735	5	5,849	10
Sum	57,255	100	58,814	100
< 50	5,218	9	5,986	10
50–59	15,760	28	15,385	26
60–74	30,591	53	29,737	51
≥ 75	5,686	10	7,706	13
Total	57,255	100	58,814	100

Figure 1. Unadjusted 10-year survival (with 95% CI) of the stem brands used in the Danish-Norwegian-Swedish subgroup, with stem revision for aseptic loosening as the endpoint. The 7 stem brands used in the Danish-Norwegian-Swedish subgroup that were not included in this analysis had fewer than 25 hips at risk after 10 years, and were therefore excluded. Stems are ordered by survival estimates, in descending order.

Figure 2. Survival of non-HA-coated and HA-coated Bimetric stems for females aged 60–74 with a diagnosis of osteoarthritis, with the endpoint stem revision for aseptic loosening in an adjusted Cox regression model.